Combining-Ziprasidone-Carbamazepine

From Psychiatrienet
Revision as of 14:22, 8 June 2010 by Mariska (talk | contribs) (Created page with '{{Drugcombi | base = ziprasidone | add = carbamazepine | info = * This combination of drugs may have possible synergistic effects. * Induction of CYP3A4 by carbamazepine may m...')
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Ziprasidone
Type Antipsychotic
Group Atypical AP
Other use Moodstabilizer
links
Medscape Ziprasidone
PubChem 60854
PubMed Ziprasidone
Wikipedia Ziprasidone
Carbamazepine
Type moodstabilizer
Group anticonvulsant
links
ATC-code N03AF01
Medscape Carbamazepine
PubChem 2554
PubMed Carbamazepine
Drugs.com carbamazepine
Kompas (Dutch) Carbamazepine
Wikipedia Carbamazepine

Adding carbamazepine to ziprasidone.

Infobord.png General information
  • Ziprasidone is metabolized by CYP1A2 (minor) and CYP3A4.
  • Carbamazepine is principally metabolized by CYP3A4, and is a potent inducer of CYP1A2, CYP2C9, CYP3A4 and UDP-glucuronosyltransferases.
  • This combination of drugs may have possible synergistic effects.
  • Induction of CYP3A4 by carbamazepine may modestly influence the plasma level of ziprasidone. Ziprasidone dose modifications are unlikely to be necessary in patients receiving potent CYP450 3A4 inducers.[5]
Eenrichtingbord.png Start carbamazepine
  • Start carbamazepine according to the general dosing advice.



The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.